NCT05274295Unknown不适用
Open Label Single Arm Proof of Concept Trial to Evaluate the Efficacy and Safety of Cytori Celution System in Diabetic Leg Ulcers
Szeged University1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2022年2月28日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Reduction rate of the wound size
研究概览
简要总结
To evaluate the efficacy and safety of Cytori Celution System in Hungarian patients with diabetic leg ulcers.
详细描述
This motive trial can help to establish rutine application of this internationaly widely used device at University of Szeged. The primary outcome is the reduction rate of the wound size. The treatment response will be calculated from wound size before and after treatment. Any AEs related to the study devide will be monitored.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Device Feasibility
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Males or females age ≥ 18
- •At least one diabetic leg ulcer with the following condition 3.
- •Ulcer is present beyond 2 months 3.
- •Conservative treatment not leading to improvement 3.
- •Wound size between ≥5 and ≤100 cm2
- •Ability to safely undergo tissue harvest that is anticipated to yield >100mL of adipose tissue at a site that is free from infection and injury
- •Patients diagnosed with diabetes mellitus
- •Able and willing to work with the doctor, adhere to therapeutic prescriptions and appear on prescribed examinations
- •Normal or clinically not significant abnormal values based on investigator judgement on white blood cell count (WBC), C-reactive protein (CRP), Platelets, international normalized ratiod (INR), partial thromboplastin time (APTT), haemoglobin (Hgb), Renal and Liver function
- •Females of childbearing potential must have a negative pregnancy test at the Screen Visit
- •Females of childbearing potential must agree to use a highly effective method of birth control during the study. A highly effective method of birth control is defined as one which has a proven low failure rate of less than 1%
排除标准
- •More than 20% change in surface area of target ulcer between screening and renrollment visit.
- •There is bone involvement in case of ulcer
- •Patient with a history of bleeding disorder
- •Therapy for anticoagulation
- •Patient receiving corticosteroids, immunosuppressive or cytotoxic agents, and all systemic agents that can affect wound repair
- •Patient with any treatment that might interfere with the assessment of the study treatment
- •Pregnant or likely to become pregnant or lactating women
- •Participation in any type of clinical investigation concurrently or in the last 6 months
- •Positive for HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) and syphilis (results within 1 month are acceptable)
- •Any concurrent disease or condition that, in the opinion of the investigator, would make the patient unsuitable for the participation in the study.
- •Active cancer during chemotherapy or radiotherapy, or recent cancer, if the remission had place less than 5 years before joining the study (except basal cell skin cancer)
- •Patient currently undergoing dialysis for renal insufficiency (serum creatinine ≥2 mg/dL)
- •In the opinion of treating physician, patient not expected to survive beyond 30 days
- •Subjects with psychiatric conditions that are anticipated to result in protocol noncompliance
- •Uncontrolled chronic disease
- •Patient with history of severe alcohol or drug abuse
- •Lack of patient's cooperation
- •Use with blood thinners within 8 weeks of enrollment, patients treated with Acetylsalicil Acid (ASA) are allowed to be enrolled. For these patients ASA therapy has to be swiched to Low Molecular Weight Heparin (LMWH) at screening (after cardiology consultation) for one week. LMWH has to be skipped on enrollment visit and ASA has to be re-started as soon as possible after lipoaspiration performed.
- •Systemic treatments with a possible effect on ulcers within 4 weeks prior to enrollment with the following exceptions:
- •Ustekinumab (within 16 weeks prior to enrollment)
- •Adalimum, infliximab, alefacept (within 8 weeks prior to enrollment)
研究组 & 干预措施
Cytori Celution System in Chronic Non-Healing diabetic Leg Ulcers
Experimental
On the screening visit, the study physician will assign one eligible ulcer, as the target ulcer. Target ulcer will be treated and followed up during the whole study period. After liposuction investigational device will be applied on the target ulcer. After completion of Day1 visit all subjects enter the observation period and will come back to 3 on-site visits on day 7 day 14 and day 28
干预措施: Diabetic leg ulcer treatment with adipous SVF (Device)
结局指标
主要结局
Reduction rate of the wound size
时间窗: 28 days
The treatment response will be calculated from wound size before and after treatment.
次要结局
- Wound closure at Day 28(28 days)
- Improvement of Quality of Life (QoL) - EQ-5D-5L(25 days)
- Improvement Wound pain(28 days)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Open Label Single Arm Proof of Concept Trial to Evaluate the Efficacy and Safety of Cytori Celution System in Chronic Non-Healing Venous Leg UlcersAdipose-Derived Mesenchymal Stem CellsVenous Leg UlcerMesenchymal Stem CellsAutologous Adipose Stromal Vascular FractionNCT05165459Szeged University10
已完成
1 期
Open-label Investigation of the Safety and Effectiveness of DIABECELL® in Patients With Type 1 Diabetes MellitusType 1 DiabetesNCT01739829Diatranz Otsuka Limited8
终止
1 期
Phase I/II Clinical Study of 1A46 Drug SubstanceAdvanced MalignanciesNCT05987605BioRay Pharmaceutical Co., Ltd.4
已完成
不适用
Feasibility Study of a Transdermal Continuous Glucose Monitoring (CGM) System in Diabetic PatientsDiabetesNCT05133973EyeSense GmbH15
已完成
2 期
ATX-MS-1467 in Multiple SclerosisMultiple SclerosisNCT01973491Merck KGaA, Darmstadt, Germany37